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ABSTRACT
The increased cap-independent translation of anti-
apoptotic proteins is involved in the development of
drug resistance in lung cancer but signalling events
regulating this are poorly understood. Fibroblast
growth factor 2 (FGF-2) signalling-induced S6 kinase
2 (S6K2) activation is necessary, but the downstream
mediator(s) coupling this kinase to the translational
response is unknown. Here, we show that S6K2 binds
and phosphorylates hnRNPA1 on novel Ser4/6 sites,
increasing its association with BCL-XL and XIAP
mRNAs to promote their nuclear export. In the cy-
toplasm, phosphoS4/6-hnRNPA1 dissociates from
these mRNAs de-repressing their IRES-mediated
translation. This correlates with the phosphorylation-
dependent association of hnRNPA1 with 14-3-3 lead-
ing to hnRNPA1 sumoylation on K183 and its re-
import into the nucleus. A non-phosphorylatible,
S4/6A mutant prevented these processes, hindering
the pro-survival activity of FGF-2/S6K2 signalling.
Interestingly, immunohistochemical staining of lung
and breast cancer tissue samples demonstrated
that increased S6K2 expression correlates with de-
creased cytoplasmic hnRNPA1 and increased BCL-
XL expression. In short, phosphorylation on novel N-
term sites of hnRNPA1 promotes translation of anti-
apoptotic proteins and is indispensable for the pro-
survival effects of FGF-2.
INTRODUCTION
Deregulation of apoptotic cell death is a hallmark of cancer
and is involved in the development of resistance to therapy.
This is a leading cause of fatalities from common cancers in-
cluding lung cancer. Several proteins can mediate cell death
resistance (1–3) including fibroblast growth factor 2 (FGF-
2) (4–6). Indeed, we have shown that FGF-2 signalling
leads to the assembly of a multi-protein complex compris-
ing BRaf, protein kinase C and ribosomal S6 kinase 2
(S6K2) but not S6K1. The activation of S6K2 occurs in a
stepwise manner initiated by phosphorylation of the three
proline-directed serines in the auto-inhibitory domain, Ser-
410, Ser-417 and Ser-423 downstream of MEK/ERK sig-
nalling. Subsequently, phosphorylation of Ser-370 then en-
ables phosphorylation of Thr-388 by the mTORC1 com-
plex followed by that of Thr-228 by PDK1 (7). Activated
S6K2 then enhances the translation of anti-apoptotic pro-
teins such as BCL-XL and X chromosome-linked inhibitor
of apoptosis (XIAP) (4). Translation of these mRNAs un-
der conditions of cellular stress including anti-cancer thera-
pies is mediated by an internal ribosomal entry site (IRES)
located in the 5′ untranslated region (UTR) (8–10). How-
ever, we only have limited understanding of the modulators
of IRES-based translation downstream of S6K2 activation
(11). S6K2 shuttles between the nucleus and the cytoplasm
in response to growth factor signalling. In addition to its
diffuse nuclear localization, a proportion of S6K2, but not
S6K1, has been shown to co-localize with CTR453 and  -
tubulin at the level of the centrosome (7).
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The hnRNP family comprises at least 20members termed
hnRNPA1 to hnRNPU (12). These proteins are mainly lo-
cated in the nucleus, associated with pre-mRNA to influ-
ence their splicing, metabolism and transport with some hn-
RNPs reported to shuttle between the nucleus and the cyto-
plasm (12). Among these, hnRNPA1 was shown to contain
a novel nuclear localisation signal, calledM9, which enables
both its nuclear entry and exit (13). Interestingly, interfering
with hnRNPA1 shuttling, and the resulting accumulation of
this protein in the cytoplasm, prevents BCL-XL and XIAP
expression in several cell systems (9,10,14). Moreover, when
hnRNPA1 is bound to these mRNAs, it suppresses IRES-
mediated translation (9,10,15–17). However, the regulation
of this hnRNPA1 activity downstream of cellular signalling
is not understood.
Here, we identified hnRNPA1 as a distinct substrate for
S6K2 downstream of FGF-2 signalling that is crucial for
the anti-apoptotic function of this pathway. We found that
FGF-2 signalling promotes the cycling of hnRNPA1 be-
tween the nucleus and the cytoplasm through a series of
stepwise post-translational modifications. FGF-2 stimula-
tion and S6K2 activation lead first to the phosphoryla-
tion of hnRNPA1 on a novel site (Ser4) that promotes the
binding of this protein to BCL-XL and XIAP mRNAs.
Then, following association with the export factor Nxf-1,
hnRNPA1/mRNA complexes are exported from the nu-
cleus in a MEK-dependent fashion. Finally, once in the cy-
toplasm, phosphorylated hnRNPA1 interacts with 14-3-3
and  leading to its sumoylation on K183. This last event
is necessary for the re-import of hnRNPA1 and subsequent
shuttling cycles as sumo-deficient mutants for this site accu-
mulate in the cytoplasm. In short, our work demonstrates
a previously undescribed mechanism through which FGF-
2 signalling increases the export of BCL-XL and XIAP
mRNAs out of the nucleus and promotes their subsequent
translation. Targeting the enzymes that regulate these post-
translational modifications may provide a novel and effi-
cient way to silence this pro-survival signalling mechanism





pCEMM-GS-TAP vector was a kind gift fromDrA. Bauch
(18). pCMV6-hnRNPA1-FLAGwas fromOrigene andmu-
tations (S4AS6A, S4DS6D and K183R) introduced by di-
rected mutagenesis. The Myc-MBP-M9M construct was
from Dr Y. M. Chook (19). HA-SUMO1 construct was ob-
tained via Addgene (21154) from Dr J. Yuan (20).
Cell culture
H510 and HEK293 cells were maintained in RPMI-1640
or Dulbecco’s modified Eagle’s medium, respectively, with
10% foetal calf serum (FCS). Prior to FGF-2 treatment,
cells were starved in FCS-free media (21) for 3 days (H510)
or overnight in 0.5% FCS media (HEK293). DNA con-
structs were transfected using Attractene and siRNAs (20
nM) with Lipofectamine RNAiMAX (according to manu-
facturer’s protocol).
Dimethyl-labelling quantitative phosphoproteomics
H510 cells grown in serum-free medium (21) were treated
± 0.1 ng/ml FGF-2 or 10 ng/ml SCF for 10 min at 37◦C,
5% CO2. Stimulated and unstimulated samples were then
subjected to differential dimethyl-labelling using heavy or
light formaldehyde as previously described (22). Phospho-
peptides were enriched using immobilized metal affinity
chromatography method (23) and samples analysed using
LC-MS/MS QSTAR ELITE mass spectrometer (Applied
Biosystems).
TAP-tag purifications
S6K2 and hnRNPA1 open reading frames (ORFs) were
cloned into the GS-TAP vector by gateway technology
(Invitrogen) to produce Protein G and streptavidin bind-
ing peptide N-terminal fusion constructs. HEK293 cells
expressing TAP-S6K2 or TAP-hnRNPA1 were treated ±
FGF-2 for 10 min, lysed in LB (50 mM Tris/HCl, pH 7.5,
125 mMNaCl, 5% glycerol, 0.2% NP-40, 1.5 mMMgCl2, 1
mM DTT, 25 mM NaF, 1 mM Na3VO4, 1 mM EDTA and
protease inhibitors) and lysates cleared by centrifugation.
These were incubated with rabbit IgG agarose (Sigma) (2 h,
4◦C). Bound proteins were washed three times in LB and
twice with TEV cleavage buffer (10 mM Tris/HCl, pH 7.5,
150 mM NaCl, 0.5 mM EDTA, 0.2% NP-40) and eluted
by incubating with 100U of TEV protease (2 h, 16◦C).
TEV cleaved lysates were incubated with Streptavidin beads
(Pierce) (2 h, 4◦C) and washed four times with cleav-
age buffer supplemented with protease/phosphatase in-
hibitors. Bound proteins were eluted by boiling in Laemmli
buffer and separated on a 4–15% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). Protein
lanes were excised as 1 mm gel slices and digested with
trypsin. Peptides were analysed using an orthogonal ac-
celeration quadrupole Tof mass spectrometer (SYNAPT
HDMS,Waters, UK). Liquid Chromatography/Mass spec-
trometry (LC/MS/MS) data were then searched against a
non-redundant protein database (UniProt 12.4) using the
Mascot search engine (Matrix Science, UK) and analysed
using the Scaffold software.
Phosphopeptide arrays
14-aa long overlapping peptides covering hnRNPA1 were
synthesized and spotted on nitrocellulose membranes (Sup-
plementary Figure S5). The arrays were washed extensively
in kinase buffer (20 mM Tris pH 8, 20 mM MgCl2, 2 mM
MnCl2) prior to in vitro kinase assay with recombinant ki-
nases, 32P-ATP and cold ATP in kinase buffer (15 min,
37◦C). The reactions were stopped with ethylenediaminete-
traaceticacid (EDTA) and the arrays washed once with 1M
NaCl (20 min), followed by 1% SDS (20min) and 15 washes
with 0.5%phosphoric acid. Following a final washwith 96%
ethanol, the arrays were autoradiographed.
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Subcellular fractionation
Cells were re-suspended in fractionation buffer (10 mM
HEPES pH 7.6, 3 mMMgCl2, 10 mM KCl, 5% (v/v) glyc-
erol, 1% Triton-X100, protease/phosphatase inhibitors) on
ice for 10 min and then centrifuged at 250 g (5 min, 4◦C).
The supernatant was further centrifuged (18 000 g, 10 min)
to obtain a cleared cytoplasmic fraction. The pellet was
washed in ice-cold wash buffer (10 mM HEPES pH 7.6,
1.5 mM MgCl2, 10 mM KCl, protease/phosphatase in-
hibitors) (250 g, 5 min, 4◦C) prior to re-suspension in nu-
clear extraction buffer (20 mM HEPES pH 7.6, 1.5 mM
MgCl2, 420 mMNaCl, 25% (v/v) glycerol, 0.2 mM EDTA,
protease/phosphatase inhibitors) and sonicated (30 min in
ice-cold water). The lysate was then centrifuged (18 000 g,
10 min, 4◦C) and the supernatant transferred to fresh tubes
as the crude nuclear extract.
Co-immunoprecipitation
Antibodies were conjugated to Protein A or G magnetic
beads (Dyanal). When following subcellular fractionation,
the cytoplasmic fraction was mixed with equal volume of
IP dilution buffer (90 mM HEPES pH 7.6, 240 mM Nacl,
1% NP40, 4 mM EDTA, protease/phosphatase inhibitors)
and the subsequent washes performed with 0.5X IP di-
lution buffer. For SUMO immunoprecipitations, N-ethyl
malaeimide (20 mM) was added to the IP and wash buffers.
RNA immunoprecipitation
RNA immunoprecipitation (RNA-IP) was performed as
described in (24). Antibody-conjugated magnetic beads (A
or G) were used to immunoprecipitate hnRNPA1 from the
cytoplasmic or nuclear extracts; the associated mRNA was
reverse transcribed into cDNA and analysed by quanti-
tative polymerase chain reaction (qPCR). For primer se-
quences see SupplementaryMaterials. Absolute quantifica-
tion ofmRNAswas performed in SDS 2.4 software (ABI in-
struments) using a standard curve from serial dilution of the
input. Samples were normalised to their corresponding in-
put and presented as a percentage of input as previously de-
scribed (25). The levels of immunoprecipitated protein and
the amounts of input RNA corresponding to the RNA-IPs
in Figure 5 are presented in Supplementary Figure S7.
Synthetic RNA preparation
Radioactive BCL-XL or XIAP 5′-UTR RNAs for UV
crosslinking and nitrocellulose filter binding assays were
prepared by in vitro transcription. KOD PCR was used
to generate DNA templates for in vitro transcription. For
T7 primer sequences see Supplementary Materials. Gel-
purified products (Ultra CleanTM 15, MO BIO Laborato-
ries) were in vitro transcribed in the presence of 32P UTP
(10–25 mCi/ml) using Maxiscript kit (Ambion) and gel
purified. Full-length RNA bands were cut out and eluted
in water overnight before purification (RNA miniprep
columns; Agilent Technologies). Monocistronic RNA re-
porters (mono BCL-XL ormonoCAT) containing the chlo-
ramphenicol acetyltransferase (CAT) reporter gene used in
RNA transfections were prepared as described previously
(26).
CAT reporter analysis
Determination of CAT expression from transfected in vitro
synthesized RNA reporter constructs was as previously de-
scribed (26).
UV crosslinking of RNA–protein complexes
RNA–protein UV crosslinking and nitrocellulose filter
binding assays were done as previously (10).
Immunohistochemistry
Tissue microarray (TMA) samples from lung cancer pa-
tients (n = 204) or breast cancer patients (n = 194) were
stained for S6K2, hnRNPA1 and BCL-XL and staining
scores calculated as described earlier (27,28). Please see
Supplementary Methods for further details.
RESULTS
S6K2 interacts with and phosphorylates hnRNPA1
We have previously shown that S6K2 mediated the pro-
survival activity of FGF-2 by promoting the translation
of the anti-apoptotic proteins BCL-XL and XIAP in sev-
eral cell types including H-510 SCLC and HEK-293 cells
(4). Here, two independent strategies were used to iden-
tify proteins that mediate this translational effect. The first
approach employed quantitative phosphoproteomic analy-
sis of H510 cells (Supplementary Table S1) and the second
utilised Tandem Affinity Purification (TAP) using S6K2 as
bait in HEK293 cells (Figure 1A and Supplementary Ta-
ble S2). Both experimental approaches were performedwith
and without FGF-2 stimulation. To help focus on changes
linked to the pro-survival activity of FGF-2, we repeated
the quantitative phosphoproteomic experiments in the pres-
ence of an alternate stimulus, stem cell factor (SCF) (Sup-
plementary Table S3), which is involved in the prolifera-
tion (29–31), but not survival, of lung cancer cells (our un-
published observations). These experiments revealed sev-
eral RNA binding proteins among which PDCD4 (11)
and hnRNPA1 interacted with S6K2 and were specifically
phosphorylated in an FGF-2-dependent manner (Figure
1A, Supplementary Tables S1 and S2 and Supplementary
Figure S1A). We have recently shown that PDCD4 is in-
volved in FGF-2/S6K2 signalling (11) but the role of hn-
RNPA1 in this process is unknown. We initially confirmed
that S6K2 and hnRNPA1 could associate in an FGF-2-
dependent fashion using co-immunoprecipitation in both
H510 (Figure 1B) and HEK293 (Figure 1C) cells. Sim-
ilarly, hnRNPA1 and S6K2 also co-immunoprecipitated
with PDCD4, suggesting that these three proteins may be
part of the same molecular complex (Figure 1C). The asso-
ciation of S6K2 with hnRNPA1 was time dependent peak-
ing 10 min following FGF-2 stimulation (Figure 1B). We
also confirmed that FGF-2 could induce the phosphory-
lation of hnRNPA1. Indeed, both hnRNPA1 splice vari-
ants were phosphorylated following FGF-2 stimulation of
32Pi phosphate labelled H510 cells (Figure 1D). To inves-
tigate whether S6K2 could be the kinase mediating hn-
RNPA1 phosphorylation, we used HEK293 cells express-
ing a tetracycline-inducible kinase-active (KA) version of
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Figure 1. hnRNPA1 interacts with and is phosphorylated by S6K2. (A)
HEK293 cells expressing TAP-tagged S6K2 were subjected to Tandem
Affinity Purification, proteins separated by SDS-PAGE and the silver
stained bands identified by MS. (B and C) S6K2 or hnRNPA1 were im-
munoprecipitated from H510 (B) or HEK293 (C) cells treated with FGF-
2 and associated proteins detected by western blot. (D) HEK293 cells
were labelled with 32Pi phosphate prior to treatment with FGF-2 and hn-
RNPA1 immunoprecipitation. The samples were separated by SDS-PAGE
and autoradiographed. (E) HEK293 cells expressing tetracycline-inducible
kinase-active S6K2 were labelled with 32Pi phosphate and hnRNPA1 im-
munoprecipitation performed post treatment± doxycline (Dox). The sam-
ples were separated on SDS-PAGE prior to autoradiography. (F) Recom-
binant (r) hnRNPA1 and S6K2 were used in an in vitro kinase (IVK) assay
in presence of 32P ATP, prior to SDS-PAGE and autoradiography. (D, E
and F) ‘C’; silver stain control. (G) hnRNPA1 peptide arrays were spot-
ted on nitrocellulose membrane and IVK assays performed with rS6K2,
rS6K1 or rAkt1 in presence of 32P ATP prior to autoradiography. Ribo-
somal S6 peptide (S6) was used as a positive control. Two peptides uniquely
phosphorylated by S6K2 are circled. All experiments are representative of
at least three independent repeats. See also Supplementary Tables S1–S4
and Supplementary Figure S1.
S6K2 (4). This revealed that increased S6K2 activity led
to phosphorylation of hnRNPA1 in 32Pi labelled cells (Fig-
ure 1E). This was a direct effect as an in vitro kinase as-
say performed in the presence of recombinant hnRNPA1,
recombinant active S6K2 and 32P-ATP resulted in hn-
RNPA1 phosphorylation (Figure 1F). AGC family kinases
such as S6K2 target the consensus sequence R–X–R–X–
X–S/T (32), but additional specificity of individual family
members is poorly documented. We therefore next inves-
tigated whether S6K2 targeted a specific phosphosite(s) in
hnRNPA1 distinct from those that may be phosphorylated
by the closely related S6K1 and the prototypical AGC ki-
nase, AKT. Peptide arrays fully covering hnRNPA1 as a se-
ries of overlapping 14 amino acid sequences were printed
onto nitrocellulose and subjected to equal units of activity
of recombinant S6K2, S6K1 or AKT. Figure 1G shows that
while all three kinases phosphorylated various sites in hn-
RNPA1, some peptides were specifically targeted by S6K2.
These included a region with the minimum sequence 1-M S
K S E S P-7 situated at the N-terminus of the protein (Fig-
ure 1G, circled). As both Ser4 and Ser6 had been identified
in our quantitative phosphoproteomic approach (Supple-
mentary Table S1), we decided to focus on understanding
the biological role of these post-translational modifications.
However, before attempting this we wished to confirm the
relevance of hnRNPA1 in controlling BCL-XL and XIAP
translation.
hnRNPA1 binds BCL-XL and XIAP mRNAs and represses
their translation
We have previously shown that hnRNPA1 binds the 5′-
UTR of XIAP mRNA and inhibits the translation of this
protein (10). We confirmed that the overexpression of hn-
RNPA1 decreased BCL-XL protein levels in HEK293 cells
(Figure 2A). Using radio-labelled RNA binding assays, we
showed that hnRNPA1 bound to the 5′-UTR of BCL-XL
andXIAPmRNAswith comparable affinity (Figure 2B and
C), but not to the 5′-UTR of the related IAP, cIAP-1. The
5′-UTRs of BCL-XL and XIAP mRNAs differ from that
of cIAP-1 in that they contain IRESs that regulate their
cap-independent translation (10). Hence, we tested whether
the ability of hnRNPA1 to bind the IRES of BCL-XL
and XIAP could control the translation from these IRESs.
HEK293 cells were transfected with a bicistronic vector (11)
where CAT expression was driven by either the BCL-XL or
XIAP 5′-UTR (cap-independent), while beta-galactosidase
expression (used for normalisation of CAT activity) was
cap-dependent. In agreement with the effects observed on
BCL-XL and XIAP levels (Figure 2A), Figure 2D shows
that co-expression of hnRNPA1 resulted in a drop of cap-
independent translation from both the XIAP and BCL-
XL IRESs. Conversely, stimulation of HEK293 cells con-
taining the BCL-XL bicistronic vector with FGF-2 for 4
h resulted in enhanced cap-independent translation (Fig-
ure 2E) that correlated with increased levels of BCL-XL
and XIAP proteins (Figure 2F). Similarly, transfection of
the BCL-XL bicistronic vector into HEK293 cells contain-
ing tetracycline-inducible KA-S6K1 or 2 showed that while
induction of KA-S6K1 did not regulate cap-independent
translation, KA-S6K2 increased IRES-driven CAT activ-
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Figure 2. hnRNPA1 binds to BCL-XL, XIAP transcripts in vitro and regulates their translation. (A) N-term GFP- and C-term FLAG-tagged hnRNPA1
were transiently expressed inHEK293 cells andwestern blotting (WB) performed for the indicated proteins 72 h later. (B andC) RecombinantGST-hnRNP
A1 was incubated in the presence of 32P-labelled, in vitro transcribed BCL-XL, XIAP or cIAP1 (negative control) 5′-UTR RNAs and UV crosslinked.
(B) RNA–protein complexes were analysed by SDS-PAGE/autoradiography. GST was used as a negative control. (C) Increasing concentrations of GST-
hnRNPA1 were used to bind the UTRs and the signal from nitrocellulose filter binding assays quantified by beta counter. (D, E and G) Bicistronic DNA
constructs containing XIAP or BCL-XL IRES elements were co-transfected into (D) HEK293 cells along with GFP (EV) or GFP-hnRNPA1 (GFP-A1)
expressing plasmids, (E) transfected into HEK293 cells treated ± FGF-2 for 4 h or (G) into HEK293 cells stably expressing tetracycline-inducible kinase-
active (KA) S6K1 or 2 treated overnight ± doxycline (Dox). IRES activity was measured as ratio of CAT to -gal expression. (F andH) HEK293 cells (F)
or S6K2-KAHEK293 cells (H) were stimulated± FGF-2 for 4 h or overnight±Dox, respectively, and samples analysed byWB for the indicated proteins.
(C, D, E and G) Results are the average of triplicates ± SEM. Student’s t-test: *P < 0.05; **P < 0.01.
ity (Figure 2G). Here again, this correlated with the ability
of KA-S6K2 to upregulate BCL-XL and XIAP protein lev-
els (Figure 2H). Together, these results confirmed that hn-
RNPA1 binds to the 5′-UTRs of BCL-XL and XIAP mR-
NAs to repress IRES-mediated translation and suggest that
KA-S6K2 might reverse this process.
Phosphorylation of hnRNPA1 on Ser4 and 6 regulates BCL-
XL and XIAP translation
The preceding findings suggested that FGF-2/S6K2-
induced phosphorylation of hnRNPA1 on Ser4 and/or 6
might enhance translation of BCL-XL and XIAP. To test
this we generated wild-type (WT), non-phosphorylatable
(S4A-S6A) and phospho-mimetic (S4D-S6D) versions of
hnRNPA1. HEK-293 cells expressing comparable amounts
of these proteins were treated with or without FGF-2 and
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analysed by western blotting. We confirmed that overex-
pression of WT-hnRNPA1 reduced basal levels of BCL-
XL and XIAP (Figure 3A). In contrast, the S4A-S6A mu-
tant failed to repress the basal expression of these pro-
teins but did prevent their induction by FGF-2. How-
ever, the S4D-S6D hnRNPA1 mutant increased the basal
BCL-XL and XIAP levels by over 2-fold (Figure 3A) and
did not prevent their further induction by FGF-2. We
therefore hypothesized that the Ser4/6 phosphorylated hn-
RNPA1 could mediate cap-independent upregulation of
BCL-XL and XIAP induced by FGF-2. In agreement with
this, the phospho-mimetic S4D-S6D hnRNPA1 mutant in-
creased cap-independent translation driven by the 5′-UTRs
of BCL-XL andXIAP inHEK293 cells transfected with the
corresponding monocistronic vector (Figure 3B). Together,
these results suggest that FGF-2-induced phosphorylation
of hnRNPA1 on Ser4/6 leads to increased cap-independent
translation of BCL-XL and XIAP.
FGF-2 mediates nucleo-cytoplasmic shuttling of hnRNPA1
Protein translation occurs in the cytoplasm (33) while hn-
RNPA1 is predominantly nuclear (34). We therefore in-
vestigated whether FGF-2 signalling could mediate the ef-
fects of hnRNPA1 on translation by controlling its subcel-
lular distribution. Cellular fractionation studies inHEK293
cells revealed a peak of cytoplasmic hnRNPA1 15 min fol-
lowing FGF-2 stimulation, followed by a drop of the lev-
els of this protein below background levels at later time
points (Figure 4A and Supplementary Figure S2A). The
cytoplasmic accumulation of hnRNPA1 was dependent on
MEK/ERK signalling as this was blocked by the MEK
inhibitors PD098059 or U1026 (Figure 4B). However, the
downstream target of MEK/ERK, S6K2 (21), did not af-
fect the increase in cytoplasmic hnRNPA1 levels as siRNA-
mediated silencing of this kinase failed to block the peak
of hnRNPA1 at 15 min (Figure 4C). Nevertheless, S6K2 si-
lencing prevented the subsequent drop in hnRNPA1 levels
(Figure 4C). The rapid changes in cytoplasmic levels of hn-
RNPA1 could be due to nucleo-cytoplasmic shuttling. As
most cellular hnRNPA1 resides in the nucleus with very lit-
tle being present in the cytoplasm (Supplementary Figure
S2A) it was impossible to visualise either by immunofluo-
rescence or biochemical techniques an early reduction or
late increase in the nuclear hnRNPA1 levels upon FGF-2
treatment. An alternative explanation for the effects seen
could reside in altered hnRNPA1 degradation which might
for example be enhanced at 30 min to account for the re-
duction in cytoplasmic levels.However, neither inhibition of
the proteasome usingMG-132 (SupplementaryFigure S2B)
nor the lysosomal pathway with chloroquine (Supplemen-
tary Figure S2C) prevented the drop in hnRNPA1 levels.We
therefore further investigated the role of nuclear import as
RNPs can be transported into the nucleus via karyopherins.
These can be blocked by the peptide inhibitor M9M (19).
Expression of this molecule in HEK-293 cells efficiently
prevented the cytoplasmic drop in hnRNPA1 levels follow-
ing 60 min FGF-2 stimulation (Figure 4D). Furthermore,
siRNA-mediated silencing of the individual karyopherins,
transportin 1 or 2 (TNPO1/TNPO2), demonstrated that
downregulation of either protein prevented the decrease in
Figure 3. Phosphorylation of Ser4/6 on hnRNPA1 regulates BCL-XL
and XIAP expression. (A and B) HEK293 cells were transiently trans-
fected with wild-type (WT), mutant (S4AS6A or S4DS6D) hnRNPA1 or
vector alone (V). (A) Cells were treated ± FGF-2 for 4 h prior to SDS-
PAGE/western blotting for the indicated proteins. Lower panel: the BCL-
XL and XIAP signals were quantified and normalized to that of HSP90.
(B) Cells were subsequently transfected with reporter mRNAs driving
CAT from the BCL-XL or XIAP IRES. CAT activity was normalised to
the amount of injected mRNA. CAT alone mRNAs were used as control.
Results are average of (A, lower panel) three independent experiments ±
SEM or (B) triplicates ± SEM. Student’s t-test: *P < 0.05; **P < 0.01.
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Figure 4. hnRNPA1 shuttles between cytoplasm and nucleus in response to FGF-2. HEK293 cells alone (A), pre-treated with the MEK inhibitors
PD098059, U1026 or DMSO alone for 1 h (B), transfected with siRNA for S6K2 (C), TNPO1 and 2 (E) or NXF1 (G) or the karyopherin inhibitor
MycMBP-M9M vector or vector alone (D) were treated ± FGF-2 for the indicated time. The cytoplasmic fraction was analysed by SDS-PAGE/western
blotting (WB) for the indicated proteins. S6K2 (C), TNPO1 and 2 (E) or NXF1 (G) knockdown were confirmed by SDS-PAGE/WB (C and G) or qPCR
(E, lower panel). (A–E and G Lower panel) The hnRNPA1 signal was quantified and normalized to that of tubulin. (F) Endogenous hnRNPA1 was im-
munoprecipitated from HEK293 cells treated ± FGF-2. Immunoprecipitates were analysed by SDS-PAGE/WB for the indicated proteins. (A–G) Results
are representative of at least three independent experiments. Bar graphs are average from replicate experiments ± SEM. See also Supplementary Figure
S2.
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hnRNPA1 cytoplasmic levels (Figure 4E). Consequently,
the drop in hnRNPA1 cytoplasmic levels following long-
term stimulation with FGF-2 likely results from active im-
port of this ribonuclear-protein (RNP) into the nucleus.
Given our findings above, we considered the possibility
that nuclear export of hnRNPA1 might account for the
early increase in cytoplasmic levels of this protein after
FGF-2 stimulation. To gain a handle on proteins that might
be involved, we performed a TAP-tag experiment using hn-
RNPA1 as the bait in the absence and presence of FGF-2
for 10 min. A full list of the identified interactors and their
overlap with the S6K2 TAP results is shown in Supplemen-
tary Table S4 and Supplementary Figure S1B/C, respec-
tively.Most of the common interactors were associated with
Gene Ontology (GO) terms linked to protein translation
andRNAprocessing (Supplementary Figure S1C). Intrigu-
ingly, the hnRNPA1 TAP revealed several mRNA export
factors including NXF1 and ALY as interactors (Supple-
mentary Table S4). Since hnRNPA1 was previously shown
to interact with mRNAs in the nucleus (12) we hypothe-
sized that association of NXF1 and ALY with hnRNPA1
might be involved in mRNA export. To evaluate this, we
first tested whether NXF1 and ALY could indeed asso-
ciate with hnRNPA1 in an FGF-2-dependent manner. Co-
immunoprecipitation experiments in HEK293 cells con-
firmed that FGF-2 stimulation promoted the interaction
of NXF1 with hnRNPA1 (Figure 4F) within a time frame
consistent with its increase in the cytoplasmic fraction (Fig-
ure 4A). In contrast, ALY was constitutively bound to hn-
RNPA1 and this interaction remained insensitive to FGF-
2 stimulation (Figure 4F). Moreover, silencing of NXF1
using siRNAs prevented the initial peak in hnRNPA1 cy-
toplasmic levels following FGF-2 treatment (Figure 4G).
Thus, the changes in the cytoplasmic levels for hnRNPA1
in FGF-2-treated cells may be explained by a sequential in-
crease in export from and subsequent re-import to the nu-
cleus.
hnRNPA1 mediates the nuclear export of BCL-XL and
XIAP mRNAs in response to FGF-2
Given that hnRNPA1 binds both XIAP and BCL-XL mR-
NAs, we hypothesized that these messages were being co-
exported with this RNP from the nucleus following FGF-
2 stimulation. To test this, we performed cell fractionation
followed by hnRNPA1 immunoprecipitation and qPCR for
associated mRNAs. This revealed that the amount of BCL-
XL andXIAPmRNA co-precipitated with hnRNPA1 from
the cytoplasmic fraction increased during the first 15 min
of FGF-2 stimulation (Figure 5A). Silencing of NXF1 pre-
vented this increase (Figure 5B), highlighting the require-
ment of this component of the RNA export machinery for
this process. Moreover, the increase in mRNA export was
selective as cIAP1 and GAPDH mRNAs did not show en-
hanced export (Figure 5A). We then investigated whether
the phosphorylation of hnRNPA1 on Ser4/6 impacts on
the export of BCL-XL and XIAPmRNAs and their associ-
ation with this RNP. HEK293 cells were transfected with
the WT or non-phosphorylatable hnRNPA1 constructs.
The expressed proteins were then immunoprecipitated and
qPCR performed to assess the levels of BCL-XL and XIAP
mRNAs. Figure 5C shows that FGF-2 stimulation led to
the same increase in cytoplasmic hnRNPA1/mRNA com-
plexes as seen with the endogenous protein (Figure 5A).
However, expression of the non-phosphorylatable mutant
of hnRNPA1 prevented the increase in cytoplasmic BCL-
XL and XIAP mRNAs (Figure 5C). Importantly, this did
not appear to be a consequence of a failure to export the
mutant hnRNPA1 from the cell nucleus as this protein still
demonstrated increased abundance in the cytoplasm upon
FGF-2 stimulation (Figure 6A). These data suggest that
while phosphorylation of hnRNPA1 on Ser4/6 is not re-
quired for the nuclear export of this protein, it appears to be
necessary for the binding of the RNP to its mRNA cargo.
In agreement with this, the phospho-mimetic hnRNPA1
displayed higher affinity for BCL-XL and XIAP mRNAs
in vitro as compared to the WT or non-phosphorylatable
mutant (Figure 5D). Thus, Ser4/6 phosphorylation of hn-
RNPA1 appears to promote the export of BCL-XL and
XIAP mRNAs out of the nucleus in response to FGF-2,
thereby increasing the pool of these mRNAs to be trans-
lated. Moreover, the binding of BCL-XL or XIAP mRNA
to the S4DS6D hnRNPA1 mutant was increased in the nu-
cleus but reduced in the cytoplasm compared to WT pro-
tein (Figure 5E). Hence, further events may occur in the cy-
toplasm to enable hnRNPA1 dissociation from its mRNA
cargo promoting their translation. The results also predict
that hnRNPA1 downregulation should reduce mRNA ex-
port and lead to decreased BCL-XL and XIAP expres-
sion and FGF-2 pro-survival signalling. Indeed, siRNA-
mediated silencing of hnRNPA1 reduced BCL-XL and
XIAP protein levels (Figure 5F) and impaired the induc-
tion of these proteins in response to FGF-2 (Figure 5G).
Consequently, the FGF-2-mediated pro-survival effect to
cisplatin-induced cell death was prevented, as measured by
an increased number of cells in the sub-G1 phase of the
cell cycle (Figure 5H). Taken together, our data suggest
that FGF-2/S6K2-mediated Ser4/6 phosphorylation of hn-
RNPA1 promotes its binding to BCL-XL and XIAP mR-
NAs within the nucleus. Furthermore, once exported out-
side the nucleus this phosphorylation also appears in some
way to de-repress cap-independent translation of these mR-
NAs, thereby facilitating the pro-survival effects of FGF-2.
hnRNPA1 re-import into the nucleus is dependent on interac-
tion with 14-3-3 and  to promote sumoylation
We next focused on unravelling the mechanisms involved in
the re-entry of hnRNPA1 into the nucleus. To address this,
we first assessed the role of Ser4/6 phosphorylation in this
process. Figure 6A shows that in contrast to its WT coun-
terpart, the non-phosphorylatable hnRNPA1 mutant is ca-
pable of exiting the nucleus following FGF-2 stimulation,
but subsequently fails to be re-imported into the nucleus.
This suggested that phosphorylation of Ser4/6 residuesmay
be involved in the import process. A closer examination
of the peptide sequence surrounding these phosphosites
(MSKSESP) revealed that it closely matched a 14-3-3 con-
sensus sequence (R (S/Ar) (+/Ar) S (L/E/A/M) P). In-
teraction of cargo proteins with 14-3-3s has been shown
to regulate their nuclear import (35,36), and this requires
phosphorylation of the 14-3-3 recognition motif (37). In-
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Figure 5. hnRNPA1 mediates nuclear export of BCL-XL and XIAP mRNA in response to FGF-2. (A) HEK293 cells, (B) HEK293 cells transfected with
Nxf1 siRNAor non-targeting control (NT) siRNAor (C)HEK293 cells expressingwild-type or S4AS6Amutant hnRNPA1were treatedwithFGF-2 for the
indicated durations (A and C) or 30 min (B). The cytoplasmic fractions were subjected to RNA immunoprecipitation (RNA-IP) with hnRNPA1 antibody
and the associated RNA analysed by quantitative PCR (qPCR) using primers directed against the indicated transcripts. (D) Increasing concentrations of
recombinant wild-type (WT), S4AS6A or S4DS6D mutant hnRNPA1 were incubated with 32P-labelled, in vitro transcribed XIAP or BCL-XL 5′-UTR,
nitrocellulose filter binding assays performed and binding quantified as in Figure 2C. Kd values were calculated from three independent experiments
using non-linear one-site specific binding. (E) HEK293 cells were transiently transfected with WT, S4AS6A, S4DS6D hnRNPA1 or vector alone (V)
and subcellular fractionation was performed 48 h later to separate the nuclear and cytoplasmic fractions. These were subjected to RNA-IP and qPCR
as in (A). Results are expressed as average fold changes from triplicate ± SEM with cells expressing WT-hnRNPA1 as reference. (F) HEK293 cells were
transfected with hnRNPA1 (siA1) or luciferase (siLuc) control siRNAs or mock transfected (transfection reagent alone). Cell lysates were analysed by
SDS-PAGE/western blotting (WB). (G) HEK293 cells transfected ± hnRNPA1 or non-targeting (siNT) siRNAs and treated ± FGF-2 for 4 h followed
or not by treatment with cisplatin for 48 h were (G) analysed by SDS-PAGE/WB for their BCL-XL and XIAP levels or (H) analysed by flow cytometry
following PI staining for the appearance of a Sub-G1 (apoptotic) population. Results are average of triplicates± SEM. (G) Left panel: average of intensities
for BCL-XL and XIAP bands from three experiments were normalized to that of tubulin and plotted ± SEM. (A–H) Results representative of at least
three independent experiments. Student’s t-test: *P < 0.05; **P < 0.01.
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Figure 6. Cytoplasmic hnRNPA1 associates with 14-3-3 subunits and is sumoylated upon stimulation with FGF-2. (A, C, G and H) HEK293 cells were
transiently transfected with (A) wild-type (WT) or S4AS6A mutant hnRNPA1-FLAG or (C, G and H) siRNAs against the indicated proteins or a non-
targeting control (NT) were treated± FGF-2 for the indicated time (A and G) or 60 min (C) and the cytoplasmic fraction analysed by SDS-PAGE/western
blotting (WB). (A, G andH lower panels and C) Band intensities for hnRNPA1were quantified and normalized to that for tubulin. Results show average of
triplicate experiments ± SEM normalised to the corresponding controls. In Fig6A, lower panel shows quantification for both endogenous and the FLAG-
tagged hnRNPA1. (B) HEK293 cells were treated with FGF-2 and the endogenous 14-3-3 protein subunits ,  or  immunoprecipitated (IP) from the
cytoplasmic fraction. Immunoprecipitates were analysed by SDS-PAGE/WBfor endogenous hnRNPA1or 14-3-3 proteins. (D) Endogenous hnRNPA1was
immunoprecipitated from the cytoplasmic fraction of HEK293 cells treated ± FGF-2. Immunoprecipitates were analysed by SDS-PAGE/WB with either
Sumo1 or hnRNPA1 antibodies. The arrows indicate sumoylated-hnRNPA1. (E) HEK293 cells stably expressing HA-Sumo1 were treated with siRNA for
14-3-3,  or NT before stimulation with FGF-2. HA-SUMO1 was immunoprecipitated with anti-HA antibodies from the cytoplasmic fraction and the
samples analysed by SDS-PAGE/WB for the indicated proteins. (F and I) HEK293 cells stably expressing HA-SUMO1 were transiently transfected with
FLAG-tagged WT or S4AS6A or K183R mutant hnRNPA1 and treated with FGF-2. Cytoplasmic fractions were immunoprecipitated for HA-SUMO1
and analysed as above. All experiments are representative of three independent experiments. See also Supplementary Figure S3.
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terestingly, our TAP for hnRNPA1 revealed that the ,
 and  isoforms of 14-3-3 interacted with this RNP in
response to FGF-2 (Supplementary Table S4). We there-
fore next attempted to confirm these interactions by co-
immunoprecipitation studies in HEK293 cells. While FGF-
2 triggered an inducible interaction between hnRNPA1 and
14-3-3 and  the binding of 14-3-3 was constitutive (Fig-
ure 6B). The inducible interaction of hnRNPA1 with 14-3-
3 and  depended on Ser4/6 phosphorylation as, unlike
its WT counterpart, the non-phosphorylatable hnRNPA1
mutant failed to interact with these proteins (Supplemen-
tary Figure S3A). We therefore reasoned that 14-3-3 and
 may be necessary for the nuclear import of hnRNPA1
in response to FGF-2. In agreement with this notion, si-
lencing of either of these 14-3-3 isoforms prevented the
drop in cytoplasmic hnRNPA1 seen in the control cells fol-
lowing a 60 min treatment with the growth factor (Fig-
ure 6C). 14-3-3s often act as scaffolds promoting further
post-translational modifications to facilitate protein shut-
tling (38,39). In this regard, sumoylation of proteins has
been shown to target them for nuclear import (40,41). In-
terestingly, our hnRNPA1 TAP had revealed interactions
with a complete sumoylation machinery, including SUMO
activating enzyme 1 (SAE1), SUMO activating enzyme 2
(SAE2/UBA2), SUMO conjugating enzyme (UBC9) and
the SUMO Ligase E3 (FUS) in response to FGF-2 stim-
ulation (Supplementary Table S4). Hence, we investigated
whether stimulation of HEK293 cells with FGF-2 led to
the sumoylation of hnRNPA1. Figure 6D shows that FGF-
2 treatment induced the Sumo1 modification of hnRNPA1
in a time frame consistent with prior 14-3-3 interaction
(Figure 6B). Accordingly, silencing of 14-3-3 or  pre-
vented the sumoylation of hnRNPA1 (Figure 6E). More-
over, the hnRNPA1 S4/6A mutant that fails to bind these
14-3-3s was also not sumoylated in response to FGF-2 (Fig-
ure 6F). If sumoylation of hnRNPA1 is required for its nu-
clear import, then mutating the sumoylation site(s) or si-
lencing the machinery required for this post-translational
modification should lead to the cytoplasmic accumulation
of hnRNPA1 in response to FGF-2. Figure 6G demon-
strates that siRNA-mediated silencing of Sumo1 did not in-
hibit the exit of hnRNPA1 from the nucleus, but instead pre-
vented the subsequent re-import of this protein following
FGF-2 stimulation. Similarly, silencing of the SUMO con-
jugating enzyme, UBC9, led to cytoplasmic accumulation
of hnRNPA1 (Figure 6H). Three sumoylation sites (K3, K8
and K183) were predicted within the hnRNPA1 sequence.
To determine which of these were relevant for FGF-2 sig-
nalling, each was individually mutated. This showed that
mutation of K183 to R alone prevented sumoylation of hn-
RNPA1 (Figure 6I). Consistent with our findings, following
Sumo1 or UBC9 silencing, the non-sumoylatable K183R
hnRNPA1 mutant was prevented from re-import to the nu-
cleus following FGF-2 stimulation (Figure 6I), establishing
the requirement for these sumoylation sites in the nuclear
import of hnRNPA1. In contrast, mutation of the K3 or
K8 residues had no effect on hnRNPA1 shuttling (Supple-
mentary Figure S3B).
The in vivo relevance of our findings on the role of S6K2
signalling to the subcellular localisation of hnRNPA1 is
supported by our data from immunohistochemistry stain-
ing of lung and breast cancer tissue microarrays. Indeed,
the analysis of lung tumours from 204 patients revealed
that an increase in S6K2 staining correlates with the con-
comitant upregulation of BCL-XL (R2 = 0.9968, P =
0.009521) and decrease in cytoplasmic hnRNPA1 staining
(R2 = 0.9176, P = 0.009658) (Figure 7A and Supplemen-
tary Figure S6A). A similar pattern emerged upon analysis
of breast tumours from 194 patients whereby upregulation
of BCL-XL (R2 = 0.8587, P = 0.028862) and decrease in
cytoplasmic hnRNPA1 (R2 = 0.9793, P = 0.001522) stain-
ing correlated with an increase in S6K2 staining (Figure 7B
and Supplementary Figure S6B). Taken together, our re-
sults demonstrate that FGF-2/S6K2 signalling controls the
cycling of hnRNPA1 in and out of the nucleus using step-
wise phosphorylation and sumoylation events that drive
specific protein–protein interactions (Figure 7C). This cy-
cling is necessary for increased translation of BCL-XL and
XIAP and the pro-survival function of FGF-2.
DISCUSSION
hnRNPA1 is a substrate of S6K2 and regulates BCL-XL and
XIAP translation
We have previously shown that FGF-2/S6K2 signalling en-
hances the translation of a series of anti-apoptotic pro-
teins including BCL-XL, Bcl-2, XIAP and cIAP1/2 (4–6).
This process mediated resistance to cell death induced by
several cytotoxic drugs in lung, breast, osteosarcoma and
prostate cancer cells ((4,42) and Roy et al., unpublished
data). However, these prior studies failed to address the
molecular mechanism through which S6K2 could enhance
the translation of BCL-XL and XIAP. We previously un-
covered PDCD4 as a novel substrate of S6K2 that regu-
lates translation of mRNAs containing IRESs (11). Here,
we demonstrate that PDCD4 and S6K2 interact as part of
an FGF-2 induciblemulti-protein complex that includes the
RNA-binding protein hnRNPA1. Our data show that this
RNP is indispensable to the pro-survival response down-
stream of FGF-2/S6K2 signalling as the phosphorylation
of hnRNPA1 by S6K2 modulates its binding to the IRESs
of BCL-XL andXIAPmRNAs and upregulates their trans-
lation.
The involvement of hnRNPA1 in mRNA splicing has
been recognised for some time (43–46), but a role in
translational regulation has only recently been appreci-
ated (9,10,16,47). In particular, hnRNPA1 has been im-
plicated in the translation of mRNAs containing IRESs
in their 5′-UTRs. Such mRNAs are usually poorly trans-
lated in normal growing conditions but demonstrate en-
hanced translation in conditions of cell stress (8,48). In can-
cer, several oncogenes and tumour promoters are transla-
tionally controlled by hnRNPA1, including cMYC, Cyclin
D1, FGF-2, XIAP (10,17,49) and BCL-XL (this report), all
of which possess IRESs in their mRNAs. Our results re-
veal the stepwise mechanism by which hnRNPA1 enhances
the translation of BCL-XL and XIAP. The first step in-
volves mRNA/hnRNPA1 binding in the nucleus facilitat-
ing mRNA export to the cytoplasm. This is followed by the
cytoplasmic dissociation of hnRNPA1/mRNA complexes
to de-repress IRES-mediated translation prior to the re-
import of hnRNPA1 into the nucleus (Figure 7). This pro-
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Figure 7. Immunohistochemical staining for S6K2, hnRNPA1 and BCL-
XL. TMA samples from lung (n = 204) (A) and breast cancer (n = 194)
(B) patients were stained for S6K2, hnRNPA1 and BCL-XL. An increase
in S6K2 staining correlates with concomitant increase in BCL-XL and de-
crease in cytoplasmic hnRNPA1 staining. Patients were grouped (X axis;
group 1–4) according to their staining scores for S6K2 and correlation
curves between the staining intensities for BCL-XL and cytoplasmic hn-
RNPA1 with groups 1–4 plotted. Correlation coefficients and P-values
(ANOVA test) are shown. (C) Schematic illustration of how FGF-2 sig-
nalling regulates the shuttling of hnRNPA1 and the translation of BCL-
XL and XIAP mRNAs.
cess is selective as the export of cIAP1mRNAwas not regu-
lated by hnRNPA1 in response to FGF-2. This suggests that
a separate mechanism exists to enhance the translation of
cIAP1 downstream of FGF-2/S6K2 signalling which may
or may not include hnRNPA1. So how are these steps reg-
ulated?
Two sequential post-translational modifications control hn-
RNPA1 function
Our results reveal that these steps are controlled by at
least two sequential post-translational modifications of hn-
RNPA1: phosphorylation of Ser4/6 in the N-terminus
RNA recognitionmotif 1 (RRM1) followed by sumoylation
ofK183within theRRM2. BothRRMs have been shown to
mediate the binding of hnRNPA1 tomRNAs (50). Interest-
ingly, the N-terminus of RRM1 (where Ser4 and 6 are situ-
ated) and the C-terminus of RRM2 (where K183 is located)
were predicted through modelling to be closely juxtaposed
and to be directly involved in RNAbinding (51). Indeed, we
found that Ser4/6 phosphorylation increases the affinity of
hnRNPA1 for the IRESs of BCL-XL and XIAPmRNAs in
a cell-free system and their mRNAs in the nucleus of intact
cells. Conversely, in the cytoplasm, Ser4/6 phosphorylation
targets hnRNPA1 for sumoylation on K183, an event that
correlates with the dissociation of thisRNP frompassenger-
mRNAs. Hence, we speculate here that these two post-
translational modifications lead to conformational changes
in the RRMs that control their mRNA binding ability.
While the phosphorylation of hnRNPA1 on Ser4/6 pro-
motes nuclear export of the boundBCL-XL andXIAPmR-
NAs, in this state, translation is repressed. However, our
data suggest that, in the cytoplasm, the decrease in affin-
ity of hnRNPA1 for its cargo mRNA enables their subse-
quent translation. The latter correlates with K183 sumoy-
lation which is necessary for re-entry of hnRNPA1 into the
nucleus thereby depleting the cytoplasmic pool of this pro-
tein. We hypothesize that this depletion could facilitate hn-
RNPA1 dissociation from and translation of target mR-
NAs. This notion is supported by the observation that over-
expression of an hnRNPA1 mutant that is restricted to the
cytoplasm (10), or of the WT protein in the absence of up-
stream signalling, leads to decreased BCL-XL and XIAP
IRES activity and protein expression.
Possible relevance to cancer and areas for further investiga-
tion
At first sight, prior reports demonstrating the translational
repression of XIAP and BCL-XL through hnRNPA1 bind-
ing would suggest that overexpression of this RNP in can-
cer could be associated with reduced levels of these anti-
apoptotic proteins. This should link to enhanced respon-
siveness to cytotoxic therapies and improved patient sur-
vival. Instead, increased hnRNPA1 expression correlates
with worse patient survival (52,53). Our data now provide
a mechanism to explain this apparent conundrum. Thus,
FGF-2/S6K2 signalling enables post-translational modi-
fications of hnRNPA1 to facilitate both the nuclear ex-
port and subsequent translation of BCL-XL and XIAP
mRNAs. It is noteworthy that S6K2 activation is depen-
dent on both MEK/ERK and rapamycin-resistant mTOR
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signalling pathways (21) that are both hyper-activated in
>50% of malignancies as a consequence of activating re-
ceptor tyrosine kinase, RAS and RAF mutations or phos-
phatase inhibition (54–60). Therefore, it is tempting to spec-
ulate that S6K2 which we have previously reported to be
overexpressed in many lung cancers (4) is active in most
cases. Our in vitro data suggest that the coordinated over-
representation of both S6K2 signalling and hnRNPA1 in
tumours would be the optimal combination to stimulate
IRES-mediated translation. Moreover, these data suggest
that increased hnRNPA1 nucleo-cytoplasmic cycling rather
than expression alone would be required for this protein
to promote drug resistance. The relevance of our findings
to cancer is further supported by the fact that similar re-
sults to those in HEK293 cells were obtained in small-cell
lung cancer cells (Figures 1 and 4A–D) where FGF-2 drives
cytotoxic drug-resistance.Moreover, immunohistochemical
staining of lung and breast cancer tissuemicroarray demon-
strates that increased expression of S6K2 correlated with
increased BCL-XL and decreased cytoplasmic hnRNPA1
levels in tissue samples (Figure 7A and B and Supplemen-
tary Figure S6) providing indications of the in vivo relevance
of findings.
Although we have identified a number of the protein
partners involved in the cycling of hnRNPA1 in response
to FGF-2 signalling, some steps in this process still war-
rant further investigation. For instance, while phosphory-
lation of Ser4/6 is required to promote mRNA nuclear ex-
port through increased hnRNPA1/mRNA affinity, it is not
necessary for hnRNPA1 to exit the nucleus. Indeed, this
latter step still occurs in the absence of S6K2 as well as
with the S4A/S6A non-phosphorylatable mutant. This in-
dicates that the RNA binding and the export of hnRNPA1
are dissociated events. It also highlights that a yet uniden-
tified FGF-2-dependent, MEK/ERK-mediated signalling
event underlies hnRNPA1 nuclear exit. Published litera-
ture has involved the M9 domain of hnRNPA1 in this pro-
cess (61,62) and further FGF-2-induced post-translational
modifications may occur to regulate it. Also, while we
have shown the requirement for K183 sumoylation for hn-
RNPA1 re-import and identified through our TAP-tag pu-
rification most of the machinery involved (SAE1, SAE2,
UBC9), we have not yet found the E3-ligase responsible for
the last step of the SUMO transfer. In this regard, we did
co-purify FUS, an E3-ligase involved in Ebp1 sumoylation
(63), with hnRNPA1. However, siRNA-mediated silencing
of FUS failed to convincingly prevent K183 sumoylation in
our experimental set-up. Consequently, the E3-ligase that
fulfils this role remains to be determined.
While hnRNPA1 is not druggable per se, our data show-
ing that S6K2 activity mediates chemoresistance in lung
cancer and promotes translation of molecules linked to tu-
morigenesis ((4,11) and present results) suggests that this
kinase may be a promising novel therapeutic target for can-
cer. Pan-S6K inhibitors have been described (64) that tar-
get both S6K1 and 2. However, S6K−/−/S6K2−/− double
knockdown mice are lethal (65) suggesting that the use of
pan-S6K drugs may be toxic in the clinic. Hence, further
research into S6K2-selective drug development may lead
to efficient novel therapeutic strategies for lung and other
cancers.
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